Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.

BioMed research international - 1 Jan 2013

Chinnadurai Raghavan, Waller Edmund K, Galipeau Jacques, Nooka Ajay K

Abstract excerpt

The regenerative abilities and the immunosuppressive properties of mesenchymal stromal cells (MSCs) make them potentially the ideal cellular product of choice for treatment of autoimmune and other immune mediated disorders. Although the usefulness of MSCs for therapeutic applications is in early phases, their potential clinical use remains of great interest. Current clinical evidence of use of MSCs from both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Diseases
Share to MSC gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genetic Therapy

Share to Immunosuppression Therapy

Share to Mesenchymal Stem Cells

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 24350294
DOI: 10.1155/2013/929842
PMCID: PMC3852726

Genes

MSC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.PMID 24350294Read ↗

Genetic risk factors for sclerotic graft-versus-host disease.Semantic proximity Read ↗

Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological SourceSemantic proximity Read ↗

Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapySemantic proximity Read ↗

Genetic Polymorphisms in Regulatory T Cells: The hidden truth behind the immune system dysfunction in rheumatoid arthritisSemantic proximity Read ↗

Advances in hematopoietic stem cell transplantation for autoimmune diseasesSemantic proximity Read ↗

Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?Semantic proximity Read ↗

Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cellsSemantic proximity Read ↗

Immunogenetics of hematopoietic stem cell transplantation: the contribution of microsatellite polymorphism studies.Semantic proximity Read ↗

Haematopoietic stem cell transplantation for autoimmune diseasesSemantic proximity Read ↗

Risk assessment in haematopoietic stem cell transplantation: pre-transplant patient and donor factors: non-HLA genetics.Semantic proximity Read ↗

Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases.Semantic proximity Read ↗

Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United StatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.